A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study

Richard F. Riedel, Karla V. Ballman, Yao Lu, Steven Attia, Elizabeth T. Loggers, Kristen N. Ganjoo, Michael B. Livingston, Warren Chow, Jennifer Wright, John H. Ward, Daniel Rushing, Scott H. Okuno, Damon R. Reed, David A. Liebner, Vicki L. Keedy, Leo Mascarenhas, Lara E. Davis, Christopher Ryan, Denise K. Reinke, Robert G. Maki

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Fingerprint

Dive into the research topics of 'A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study'. Together they form a unique fingerprint.

Medicine & Life Sciences